Global Payments Inc vs Mesoblast Limited — how do they compare? Global Payments Inc trades at $86.35 (market cap $22.72B), while Mesoblast Limited trades at $16.79 (market cap $2.21B). The key difference: Global Payments Inc is far larger — about 10.3× Mesoblast Limited's market cap, and Global Payments Inc pays a 1.16% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GPN | MESO | |
|---|---|---|
Market Cap | $22.72B | $2.21B |
Sector | Industrials | Technology |
52-Week High | $90.01 | $20.96 |
52-Week Low | $62.47 | $12.88 |
Enterprise Value | $40.87B | $2.21B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $85.03, down 1.28% today, with a bullish technical signal from moving averages. Recent quarterly EPS beats and a consensus price target of $96.67 suggest upside potential, though negative net income margin and ROE highlight profitability challenges. Cash flow trends show strong operational performance, but rising debt-to-asset ratios warrant monitoring.
The outlook balances growth from Genius platform adoption against margin pressures and competitive fintech threats. Analysts are predominantly bullish, but investors should weigh earnings consistency against valuation risks and macroeconomic headwinds affecting payment volumes.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Trailing returns across standard periods
Latest headlines on both assets
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →